Novartis AG has presented yet more data on Cosentyx (secukinumab) at the European League Against Rheumatism (EULAR) congress in Amsterdam which it believes will help the drug achieve a leading position in ankylosing spondylitis (AS) and psoriatic arthritis (PsA), as well as psoriasis.
Interview: Novartis Counts On AS and PsA For Cosentyx Growth
Novartis immunology chief Eric Hughes tells Scrip a wealth of data is showing that early treatment with Cosentyx can prevent the structural changes that lead to lack of mobility in ankylosing spondylitis and psoriatic arthritis patients.
More from Immunological
More from Therapy Areas
• By
Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.
• By
The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.
• By
Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.